Sam Kim

About Sam Kim

Biomarker Scientist with 6+ years of pharma R&D experience, specializing in clinical research, multi-omics technologies & data analysis across immunology, oncology, inflammation and virology. Resourceful problem-solver with both hands-on lab experience and strong bioinformatics skills for designing and executing in-house and outsourced projects. Strong track record of supporting translational & precision medicine efforts, leveraging preclinical, clinical, public and real-world datasets to generate insights for discovery & development programs.• Commentary: “In this issue of the JCI, Nkongolo et al. report on their application of two methodological advances, liver sampling by fine-needle aspiration and single-cell RNA sequencing, to define a liver-resident CD8+ T cell population ⋯ The finding that antiviral therapy largely abolishes bystander activity underscores the importance of combining direct antiviral and immune strategies aiming at HBV functional cure.”• Dr. Michael Yaffe’s recommendation of Abseq: “This paper is a total game-changer for the field of signaling by allowing the potentially unlimited ability to profile very large numbers of signaling protein activation states in single cells ⋯ the paper will be long remembered as a classic demonstration and technical tour-de-force in the field.”

Experience

1. Principal Scientist, Biomarker

   Gilead Sciences

   Jan 2025 — Present

Education

• Stanford University

  Doctor of Philosophy - PhD, Chemistry

  2003 — 2009

• Seoul National University

  Bachelor of Science - BS, Chemistry

  1998 — 2003